Sutro Biopharma (STRO) Current Deferred Revenue (2017 - 2026)

Sutro Biopharma has reported Current Deferred Revenue for 9 years, with the latest figure at $10.6 million in Q4 2025.

• Quarterly Current Deferred Revenue fell 84.86% year-over-year to $10.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.6 million (down 84.86% YoY) and the FY2025 annual result came in at $10.6 million, down 84.86% from the prior year.
• Current Deferred Revenue rose to $10.6 million in Q4 2025 per STRO's latest filing, from $9.0 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $74.0 million in Q2 2024 and troughed at $5.5 million in Q4 2021.
• A 5-year average of $24.8 million and a median of $16.3 million in 2022 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue soared 310.09% in 2024, then plunged 87.63% in 2025.
• Over 5 years, Current Deferred Revenue stood at $5.5 million in 2021, then surged by 204.93% to $16.8 million in 2022, then increased by 23.31% to $20.7 million in 2023, then surged by 237.67% to $69.8 million in 2024, then tumbled by 84.86% to $10.6 million in 2025.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $10.6 million, $9.0 million, and $12.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.